Immunological and metabolic optimization of tumor neoantigen vaccines

Tumor initiation and progression are highly intricate biological processes, and mutation-driven tumorigenesis is a primary underlying cause. Personalized cancer vaccines have been developed to exploit these specific mutations, particularly in the form of tumor neoantigens, to induce immune responses